Evaluating the Therapeutic Efficiency and Efficacy of Blood Purification for Treating Severe Acute Pancreatitis: A Single-Center Data Based on Propensity Score Matching
Hongwei Huang,Jiacheng Mo,Gui Jiang,Zheng Lu
DOI: https://doi.org/10.2147/ijgm.s475186
IF: 2.145
2024-09-01
International Journal of General Medicine
Abstract:Hongwei Huang, 1 Jiacheng Mo, 2 Gui Jiang, 2 Zheng Lu 1 1 Intensive Care Unit, Guangxi Hospital Division of the First Affiliated Hospital, Sun Yat-Sen University, Nanning, Guangxi, 530022, People's Republic of China; 2 Intensive care unit, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People's Republic of China Correspondence: Zheng Lu, Intensive Care Unit, Guangxi Hospital Division of the First Affiliated Hospital, Sun Yat-sen University, Nanning, Guangxi, 530022, People's Republic of China, Email Purpose: To evaluate the long-term efficacy and cost-efficiency of blood purification (BP) in severe acute pancreatitis (SAP) through single-center data. Patients and Methods: A total of 155 SAP patients were collected and followed up for 6 months. The participants were divided into control (49 cases) and BP group (106 cases) according to whether they received BP treatment or not. The primary outcomes were 6-month mortality, length of hospital stay, and hospitalization costs. Propensity score matching (PSM) analysis was performed based on various factors such as gender, age, etiology, SOFA score, JSS score, and creatinine value on day 1. Results: There were significant differences in all baseline data between BP and control groups ( p < 0.05). However, there was a significant difference in the mortality, length of hospital stay, hospital costs and infection aggravation rate the in outcome data for 6-months (all p < 0.05). BP was not considered a death factor in any adjusted models, with p -values ranging from 0.81 to 0.93. The results of subgroup analysis after PSM showed that BP mode had no significant impact on prognostic indicators, but the length of ICU stay and total costs were significantly increased (all p < 0.001). There was no significant difference in mortality among the cases that did not require early intervention after 6 months ( p =0.487). However, the patients in BP group had longer ICU stays ( p =0.001) and higher hospitalization costs ( p < 0.001) compared to the control group. Conclusion: The utilization of BP therapy did not decrease the 6-month mortality in SAP patients. Additionally, BP therapy has a significant impact on the duration of ICU stay or hospitalization expenses. However, the effectiveness and cost-efficiency of this therapy are unsatisfactory, and early intervention does not enhance survival benefits. Furthermore, there was no substantial variation in survival benefits between continuous veno-venous hemofiltration (CVVH) alone and compound BP. Keywords: severe acute pancreatitis, blood purification, long-term efficacy, cost-efficiency Acute pancreatitis (AP) is an inflammatory reaction induced by the state of the pancreas caused by factors such as gallstones, alcohol, hyperlipidemia, etc. Globally, the incidence of severe acute pancreatitis is 34/100,000, and it increases constantly. 1,2 Severe acute pancreatitis (SAP) is the common acute abdominal diseases. It refers to the dysfunction of one or more organs other than the pancreas for more than 48 hours. 3 It is characterized by rapid progression, development of multiple complications, and high mortality rates. Despite the recent advances in the treatment of SAP, the mortality rate due to multiple organ dysfunction syndrome (MODS), and secondary infections is still high (20%–40%). 4 Surviving patients suffer from various secondary diseases which affect their quality of life. For example, 40% of the patients experience an abnormal glucose tolerance or type 3 diabetes after the acute phase, 5 25% experience an impairment of the pancreatic exocrine function, 6 50% of the patients with necrotizing pancreatitis experienced mobility impairment one year after the onset, and 18% of patients experienced recurrence, while 8% developed chronic pancreatitis. 7 Blood purification (BP), is a non-surgical treatment method that is vital in the treatment of SAP patients. It can effectively lower the concentration of inflammatory mediators in pancreatitis patients, shorten hospital stay, and reduce mortality rate. 8–10 However, due to the differences in study design, enrollment population, BP parameters, as well as the lack of clinical trials that investigate the effects of BP on the long-term survival and quality of life of SAP patients, there is still much debate regarding the use of this technology in inflammatory diseases, particularly pancreatitis, and sepsis. In a previous meta-analysis, 11 we reported that high-volume hemofiltration (HVHF) had a better efficacy/utility ratio than the control group and was linked to -Abstract Truncated-
medicine, general & internal